Navigation Links
AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
Date:9/22/2008

WILMINGTON, Del., Sept. 22 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the United States Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market CASODEX(R) (bicalutamide) for its licensed advanced prostate cancer indication until April 1, 2009. AstraZeneca has been working with the FDA in the investigation of the safety and effectiveness of CASODEX in a pediatric setting but will not be seeking an indication in this population.

CASODEX is currently approved in the US at a dose of 50 mg daily tablet for use in combination with a luteinizing hormone-releasing hormone analog (LHRH-A) for the treatment of advanced prostate cancer (metastatic Stage D2).

AstraZeneca has a well-established prostate cancer portfolio including hormonal treatments CASODEX, launched in 1995, and ZOLADEX(R) (goserelin acetate implant), launched in 1989. Three Phase III clinical research trials (ENTHUSE program) are currently underway to evaluate the safety and effectiveness of an investigational compound, ZD4054, in non-metastatic and metastatic hormone-resistant prostate cancer.

About Prostate Cancer

Over 186,000 men will be diagnosed with prostate cancer in the U.S. in 2008, making it the most frequently diagnosed cancer in men.(1) After lung cancer, prostate cancer is the second leading cause of cancer death in men, with an estimated 28,660 deaths in 2008.(2) One in six men will develop prostate cancer in his lifetime.

About CASODEX(R) (bicalutamide) Tablets

CASODEX at a dose of 50 mg daily is a prescription medication approved for use in combination with an injection of a luteinizing hormone-releasing hormone analog (LHRH-A) for treatment of advanced prostate cancer (metastatic Stage D2).

CASODEX at a dose of 150 mg daily is not approved for use alone or with other treatments. See full Prescribing Information under the section on "CLINICAL PHARMACOLOGY-Clinical Studies-Safet
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
2. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
3. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
4. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
5. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
6. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
10. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
11. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... health and safety of Canadians is our government,s highest priority.  Our ... at its disposal to help ensure that the drugs Canadians need ... end, Health Canada has taken decisive ... of all drug products from three plants in ... Pharmachem India Pvt Ltd , Apotex Research Private Limited ...
(Date:9/30/2014)... 2014  Tasly Pharmaceuticals, Inc., the world,s leader ... today the launch of Deepure. Deepure ... men and women concerned with supporting their overall ... age while helping keep their health care cost ... herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources ... devices in Brazil , ... China (BRIC) will see robust ... are increasingly favored over surgical procedures. Although revenues will ... resources, reimbursement challenges, prolonged device approval times and demand ...
Breaking Medicine Technology:Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
(Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
(Date:10/1/2014)... Diet Doc understands that many of their ... and their dieting attempts could be easily sabotaged by the ... diet treatments into their programs as a way to ... and effective weight loss results, it also allows patients to ... maintain their weight for the future. , Earlier versions of ...
(Date:10/1/2014)... Dar, Ethiopia, at the occasion of the Leishmaniasis ... 150 African and international leishmaniasis experts, results of ... efficacy monitoring plan, carried out by MSF, ... and Ethiopia, were presented to key decision makers ... of kala-azar with the combination of Sodium Stibogluconate ...
(Date:10/1/2014)... 01, 2014 Today marks the final ... Art Institute in Oxnard and Woodland Hills, Calif., is ... mouth rehabilitation training. , “Speaking to this group of ... procedures to get the help and care they deserve,” ... repairing previous dental work, providing cosmetic dentistry, correcting bite ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5
... , , Patient-Based Record ... , MADISON, N.J., July 20 MedPlus, the ... DGX ), today announced that NYCLIX is now sharing ... New York City using the company,s Centergy(TM) suite of ...
... , SEOUL, South Korea, July 20 ... to announce that its wholly owned subsidiary, VASKA, a ... institutional, and consumer markets, has successfully turned the first major commercial ... Royal Laundry of South San Francisco is the largest ...
... , , ... campaign in support of bipartisan health care reform. , ... Plans (AHIP), "Illness", calls for fixing health care to make sure all Americans ... , "Illness doesn,t care where you live. . .or if ...
... , , , ... Oldsmar, Fla., July 20 /PRNewswire-FirstCall/ -- Women today have a number ... of their families. Banking stem cells found in menstrual blood is one way ... injuries. Menstrual blood has been shown to contain self-renewing stem cells that may ...
... Calif., July 20 SynergEyes, Inc., the high Dk ... lens design for keratoconus patients. ClearKone(TM) is a revolutionary ... of the hybrid platform, providing superior visual acuity, centration, ... to vault the predominant irregularities of the keratoconic cornea, ...
... , , BRIDGEWATER, ... pooled results from two Phase 3 studies (DUET-1 and ... non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI) ... copies/mL) while taking INTELENCE(TM) (etravirine) tablets plus background regimen ...
Cached Medicine News:Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 2Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 3Health News:Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care 4Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Health Plans Return to Airwaves in Support of Bipartisan Reform 2Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 2Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 3Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 4Health News:C'elle(SM) Featured on ABC Action News in Tampa Bay 5Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 2Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 3Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 4Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 5Health News:96-Week Safety and Efficacy Findings Presented for INTELENCE(TM) (etravirine) As Part of HIV Combination Therapy 6
... magnification and increased stereopsis, the ... for detailed visualization to the ... is ideal for vitrectomy in ... in proliferative vitreoretinopathy extending to ...
... Volks Reinverting Operating Lens System® ... advanced wide angle viewing system ... Its unique single-element prism design, ... wide-field viewing capability have made ...
... The new Volk Blumenthal Suturelysis ... flap sutures, enabling cutting sutures which, ... relatively inaccessible. The lens provides localized ... of the suture 2-3 times, resulting ...
... Laser capsulotomy procedures are now greatly improved ... Lens. This new lens promotes precise and ... bag. Computer optimized for enhanced viewing and ... new aspheric design comes standard with LaserWindow ...
Medicine Products: